Funding will support ongoing clinical development of optogenetic therapy to restore vision.

Ray Therapeutics, a leading optogenetics company, announced today the appointment of Christopher Whitmore as Chief Financial Officer.

Top-tier syndicate led by Novo Holdings A/S and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and existing investor, 4BIO Capital.

Funds will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases.